Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label rollover study of parsaclisib for continued treatment
MOH_2023-04-17_012469Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of parsaclisib in non-Hodgkin lymphoma (NHL) and follicular lymphoma (FL), sponsored by Incyte. Primary endpoints: Continued treatment access and Safety assessment. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
parsaclisib
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2023-04-17_012469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-17_012469.